Amygdala Neurosciences
2015
FOUNDED
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
2
INVESTORS
Description
Developer of therapies designed to cure addiction. The company's therapies include a selective ALDH2 inhibitor that prevents surge in dopamine levels associated craving without changes to basal dopamine, enabling patients to quit and get rid of addiction to drugs, alcohol and smoking.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 509 Hale Street
- Palo Alto, CA 94301
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Amygdala Neurosciences’s full profile, request a free trial.
Amygdala Neurosciences Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 01-Apr-2019 | 00.000 | Completed | Startup | ||
| 4. Grant | 19-Sep-2018 | 000.00 | 00.000 | Completed | Startup | |
| 3. Seed Round | 19-May-2017 | 00.000 | 00.000 | 000.00 | Completed | Startup |
| 2. Seed Round | 10-Feb-2017 | $2M | $3.45M | 000.00 | Completed | Startup |
| 1. Seed Round | 10-Apr-2015 | $1.45M | $1.45M | 000 | Completed | Startup |
Amygdala Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Seed-2 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed-1 | 5,307,464 | $0.000100 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 25.3% |
Amygdala Neurosciences Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| National Institutes of Health | Government | 000 0000 | 000000 0 |
Amygdala Neurosciences Executive Team (5)
Amygdala Neurosciences Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Howard Jaffe | Amygdala Neurosciences | Board Member | 000 0000 | |
| Ivan Diamond Ph.D | Amygdala Neurosciences | Co-Founder, Board Member & Chief Scientific Officer | 000 0000 | |
| Louis Lange MD | Amygdala Neurosciences | Co-Founder & Executive Chairman | 000 0000 | |
| Mack Mitchell MD | Self | Board Member | 000 0000 | |
| Peter Strumph | Amygdala Neurosciences | Co-Founder, President, Chief Executive Officer and Board Member | 000 0000 |